Molecular Templates, Inc.

71 articles with Molecular Templates, Inc.

• Molecular Templates to Present at Upcoming Investor Conferences - May 17, 2022

  5/17/2022

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.

• Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

  5/12/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

• Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach

  4/12/2022

  Molecular Templates, Inc. reviews highlights from the six poster presentations on its pipeline programs that were presented at the American Association of Cancer Research (AACR) Annual Meeting 2022, taking place April 8 - April 13, 2022.

• Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors

  4/8/2022

  Molecular Templates, Inc. announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time.

• Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results

  3/28/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2021.

• Molecular Templates Strengthens Board of Directors and Management Team

  3/2/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel.

• Molecular Templates to Present at the Upcoming Investor Conferences - Mar 01, 2022

  3/1/2022

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will participate in several upcoming investor conferences.

• Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

  11/30/2021

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, provided a corporate update and outlined expected 2022 milestones.

• Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

  11/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.

• Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results

  11/15/2021

  Molecular Templates, Inc. today reported financial results for the third quarter of 2021.

• Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/20/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will present and participate in 1-on-1 investor meetings at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

  8/12/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

• Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

  7/9/2021

  Molecular Templates, Inc. today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors.

• Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference

  7/6/2021

  Molecular Templates, Inc. announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.

• Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

  5/13/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2021.

• Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting

  4/12/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported that three posters featuring data on its pipeline programs and technology platform will be presented at the  AACR Virtual Annual Meeting I , taking place April 10-15, 2021.

• Molecular Templates to Prioritize Next-Generation ETB Candidates

  4/5/2021

  Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

• Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results

  3/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2020.

• Molecular Templates to Participate in Upcoming Virtual Investor Conferences - Feb 26, 2021

  2/26/2021

  Molecular Templates, Inc. announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

• Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering

  2/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $12.65 per share.